ACLX vs. QGEN, RGEN, PCVX, RVMD, EXEL, HALO, CRSP, KRYS, IBRX, and IMVT
Should you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), and Immunovant (IMVT). These companies are all part of the "biological products, except diagnostic" industry.
Qiagen (NYSE:QGEN) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
Qiagen received 198 more outperform votes than Arcellx when rated by MarketBeat users. However, 77.05% of users gave Arcellx an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 17.38% compared to Qiagen's net margin of -38.39%. Arcellx's return on equity of 12.59% beat Qiagen's return on equity.
Qiagen currently has a consensus target price of $50.95, indicating a potential upside of 13.59%. Arcellx has a consensus target price of $78.00, indicating a potential upside of 53.60%. Given Qiagen's stronger consensus rating and higher possible upside, analysts clearly believe Arcellx is more favorable than Qiagen.
In the previous week, Qiagen had 7 more articles in the media than Arcellx. MarketBeat recorded 10 mentions for Qiagen and 3 mentions for Arcellx. Qiagen's average media sentiment score of 1.76 beat Arcellx's score of 0.63 indicating that Arcellx is being referred to more favorably in the news media.
70.0% of Qiagen shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 6.2% of Arcellx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Qiagen has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
Qiagen has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Summary
Qiagen beats Arcellx on 11 of the 19 factors compared between the two stocks.
Get Arcellx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
